TVRD
Tvardi Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-52/100
Last price
1.08
▼ 0.06 (5.26%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
1.14
Day high
1.17
Day low
1.07
Volume
148.25K
Market cap
$14.41M
P/E (TTM)
—
52W range
0.93 – 43.65
Trailing performance
Returnvs SPY
1W
-15.62%
-17.6%
1M
-43.46%
-44.6%
3M
-78.40%
-82.9%
6M
-62.11%
-80.3%
YTD
-74.88%
-89.1%
1Y
-97.32%
-113.7%
3Y
-98.21%
-180.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TVRD open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
3.25M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Apr 15, 25 | WIRK SHAHEEN Director |
STOCK | 4.19K | $0 | Direct |
| Apr 15, 25 | WIRK SHAHEEN Director |
STOCK | 439.19K | $0 | Indirect |
| Apr 15, 25 | HALL WALLACE L JR Director |
STOCK | 246.76K | $0 | Indirect |
| Feb 28, 25 | TERRILLION SCOTT M General Counsel |
SELL | 163 | $776 | Direct |
| Feb 28, 25 | POSNER CHRISTOPHER Chief Executive Officer |
SELL | 583 | $2.77K | Direct |
| Feb 4, 25 | POSNER CHRISTOPHER Chief Executive Officer |
SELL | 372 | $1.76K | Direct |
| Nov 4, 24 | POSNER CHRISTOPHER Chief Executive Officer |
SELL | 3.67K | $1.06K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
HALL WALLACE L JR |
Director | — | Stock Award(Grant) |
POSNER CHRISTOPHER |
Chief Executive Officer | 13.11K | Sale |
TERRILLION SCOTT M |
General Counsel | 7.19K | Sale |
WIRK SHAHEEN |
Director | 267.36K | Stock Award(Grant) |
Fundamentals
Market cap$14.41M
Enterprise value$-1.21M
Revenue (TTM)—
Gross profit—
EBITDA$-27.11M
Net income$-26.06M
EPS (TTM)$-2.84
Free cash flow$-16.26M
Total cash$15.77M
Total debt$145.00K
Book value / share$1.55
Shares outstanding13.34M
Float9.63M
Short % of float1.92%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.48
PEG ratio—
Price / sales—
Price / book0.70
EV / revenue—
EV / EBITDA0.05
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-126.19%
Return on assets-55.51%
Debt / equity1.73
Current ratio1.87
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $18.01M | $23.65M | $15.87M | $18.47M | -23.8% |
| Selling, general & admin | $8.74M | $4.46M | $2.80M | $2.73M | +96.0% |
| Total operating expense | $26.75M | $28.11M | $18.66M | $21.19M | -4.8% |
| Operating income | -$26.75M | -$28.11M | -$18.66M | -$21.19M | +4.8% |
| Net interest income | $1.38M | $747.00K | $1.32M | $651.00K | +84.1% |
| Pre-tax income | -$18.21M | -$29.40M | -$17.35M | -$20.54M | +38.0% |
| Net income | -$18.21M | -$29.40M | -$17.35M | -$20.54M | +38.0% |
| Net income to common | -$18.21M | -$29.40M | -$17.35M | -$20.54M | +38.0% |
| Basic EPS | -2.46 | -11.41 | -6.74 | -7.98 | +78.4% |
| Diluted EPS | -3.26 | -11.41 | -6.74 | -7.98 | +71.4% |
| EBIT | -$26.75M | -$28.11M | -$17.35M | -$20.54M | +4.8% |
| EBITDA | -$26.65M | -$28.01M | -$17.25M | -$20.45M | +4.9% |
| Basic shares | 7.40M | 2.58M | 2.58M | 2.58M | +187.5% |
| Diluted shares | 7.78M | 2.58M | 2.58M | 2.58M | +202.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $20.73M | $31.61M | $22.92M | $21.49M | -34.4% |
| Cash & short-term investments | $30.81M | $31.61M | $22.92M | $43.74M | -2.5% |
| Total current assets | $31.54M | $31.69M | $26.16M | $44.11M | -0.5% |
| Property, plant & equipment | $196.00K | $300.00K | $378.00K | $460.00K | -34.7% |
| Goodwill & intangibles | $322.00K | $385.00K | $448.00K | $511.00K | -16.4% |
| Total assets | $32.07M | $35.20M | $27.00M | $45.10M | -8.9% |
| Total current liabilities | $11.04M | $10.37M | $3.28M | $4.28M | +6.5% |
| Long-term debt | — | $30.26M | — | — | — |
| Total debt | $201.00K | $30.56M | $368.00K | $450.00K | -99.3% |
| Total liabilities | $11.13M | $126.33M | $89.06M | $90.15M | -91.2% |
| Retained earnings | -$110.45M | -$92.24M | -$62.84M | -$45.49M | -19.7% |
| Shareholder equity | $20.95M | -$91.13M | -$62.06M | -$45.05M | +123.0% |
| Working capital | $20.50M | $21.32M | $22.88M | $39.83M | -3.9% |
| Net tangible assets | $20.62M | -$91.52M | -$62.51M | -$45.56M | +122.5% |
| Shares issued | 9.38M | 9.36M | 9.36M | 9.36M | +0.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$18.21M | -$29.40M | -$17.35M | -$20.54M | +38.0% |
| Depreciation & amortisation | $95.00K | $95.00K | $95.00K | $85.00K | 0.0% |
| Stock-based compensation | $1.40M | $319.00K | $314.00K | $246.00K | +338.6% |
| Change in working capital | $508.00K | $8.64M | -$3.96M | $2.67M | -94.1% |
| Operating cash flow | -$23.50M | -$18.30M | -$21.04M | -$17.87M | -28.4% |
| Capital expenditure | — | — | — | -$50.00K | — |
| Investing cash flow | -$10.08M | $0 | $22.47M | -$22.00M | — |
| Financing cash flow | $22.70M | $27.00M | $2.00K | $4.00K | -15.9% |
| Free cash flow | -$23.50M | -$18.30M | -$21.04M | -$17.92M | -28.4% |
| End cash position | $20.73M | $31.61M | $22.92M | $21.49M | -34.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Cost of revenue | — | — | — | — | — | $0 | — |
| Gross profit | — | — | — | — | — | $2.57M | — |
| Research & development | $4.00M | $4.91M | $5.49M | $3.60M | $5.81M | — | -18.5% |
| Selling, general & admin | $2.63M | $2.14M | $2.10M | $2.33M | $3.06M | — | +22.8% |
| Total operating expense | $6.63M | $7.05M | $7.59M | $5.94M | $8.87M | — | -6.0% |
| Operating income | -$6.63M | -$7.05M | -$7.59M | -$5.94M | -$8.87M | — | +6.0% |
| Net interest income | $172.00K | $247.00K | $312.00K | $411.00K | $377.00K | — | -30.4% |
| Pre-tax income | -$6.46M | -$6.80M | -$7.28M | -$5.53M | $4.17M | — | +5.1% |
| Net income | -$6.46M | -$6.80M | -$7.28M | -$5.53M | $4.17M | — | +5.1% |
| Net income to common | -$6.46M | -$6.80M | -$7.28M | -$5.53M | $4.17M | — | +5.1% |
| Basic EPS | -0.69 | -0.73 | -0.78 | -0.59 | 0.51 | — | +5.5% |
| Diluted EPS | -0.69 | -0.73 | -0.78 | -0.59 | -1.00 | — | +5.5% |
| EBIT | -$6.63M | -$7.05M | -$7.59M | -$5.94M | -$8.87M | — | +6.0% |
| EBITDA | -$6.61M | -$7.03M | -$7.56M | -$5.91M | -$8.85M | — | +6.0% |
| Basic shares | 9.38M | 9.38M | 9.33M | 9.38M | 8.25M | — | 0.0% |
| Diluted shares | 9.38M | 9.38M | 9.38M | 9.38M | 8.46M | — | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $15.77M | $19.85M | $20.73M | $21.42M | $1.05M | — | -20.6% |
| Cash & short-term investments | $15.77M | $24.98M | $30.81M | $36.46M | $21.39M | — | -36.9% |
| Accounts receivable | — | — | — | — | — | $1.23M | — |
| Inventory | — | — | — | — | — | $900.00K | — |
| Total current assets | $17.07M | $25.33M | $31.54M | $38.44M | $43.13M | — | -32.6% |
| Property, plant & equipment | $140.00K | $168.00K | $196.00K | $223.00K | $249.00K | — | -16.7% |
| Goodwill & intangibles | $291.00K | $306.00K | $322.00K | $338.00K | $354.00K | — | -4.9% |
| Total assets | $17.52M | $25.82M | $32.07M | $39.02M | $43.75M | — | -32.1% |
| Total current liabilities | $9.11M | $11.26M | $11.04M | $11.04M | $10.68M | — | -19.1% |
| Total debt | $145.00K | $174.00K | $201.00K | $228.00K | $254.00K | — | -16.7% |
| Total liabilities | $9.13M | $11.31M | $11.13M | $11.15M | $10.82M | — | -19.2% |
| Retained earnings | -$123.71M | -$117.25M | -$110.45M | -$103.17M | -$97.65M | — | -5.5% |
| Shareholder equity | $8.38M | $14.51M | $20.95M | $27.87M | $32.93M | — | -42.2% |
| Working capital | $7.96M | $14.07M | $20.50M | $27.40M | $32.45M | — | -43.4% |
| Net tangible assets | $8.09M | $14.20M | $20.62M | $27.53M | $32.57M | — | -43.0% |
| Shares issued | 9.38M | 9.38M | 9.38M | 9.38M | 9.37M | — | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$6.46M | -$6.80M | -$7.28M | -$5.53M | $4.17M | +5.1% |
| Depreciation & amortisation | $23.00K | $24.00K | $24.00K | $24.00K | $23.00K | -4.2% |
| Stock-based compensation | $335.00K | $370.00K | $353.00K | $339.00K | $627.00K | -9.5% |
| Change in working capital | -$3.13M | $566.00K | $1.23M | $914.00K | $2.03M | -653.9% |
| Operating cash flow | -$9.23M | -$5.86M | -$5.68M | -$4.26M | -$5.87M | -57.5% |
| Investing cash flow | $5.14M | $4.98M | $5.00M | $5.35M | -$9.55M | +3.3% |
| Financing cash flow | $0 | $0 | $1.00K | -$322.00K | $24.63M | — |
| Free cash flow | -$9.23M | -$5.86M | -$5.68M | -$4.26M | -$5.87M | -57.5% |
| End cash position | $15.77M | $19.85M | $20.73M | $21.42M | $20.65M | -20.6% |
Options analytics
Put / call volume
0.33
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
+131.5% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
-50.0%
Calls bid over puts
Call volume
3
Contracts, this expiry
Put volume
1
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
2.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.63 | -0.69 | -9.3% |
| Mar 2026 | -0.72 | — | — |
| Dec 2025 | -0.57 | -0.78 | -37.3% |
| Sep 2025 | -0.96 | -0.59 | +38.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.57 | 8 | $0 | 0.0% |
| Next quarter | -0.43 | 8 | $0 | 0.0% |
| Current year | -2.30 | 8 | $0 | 0.0% |
| Next year | -2.24 | 8 | $0 | 0.0% |
Analyst targets & ownership
Mean target$9.25
High target$14.00
Low target$3.00
Implied upside756.48%
Analyst count8
ConsensusBUY
Strong buy / Buy2 / 5
Hold1
Sell / Strong sell0 / 1
Held by insiders24.36%
Held by institutions17.33%
Institutions holding78
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.21
-10.89% from price
SMA 20
1.47
-26.59% from price
SMA 50
1.73
-37.50% from price
SMA 100
2.34
-53.90% from price
SMA 200
3.05
-64.57% from price
EMA 12
1.29
-16.11% from price
EMA 26
1.49
-27.51% from price
EMA 50
1.77
-38.86% from price
RSI (14)
27.9
Oversold
MACD (12,26,9)
-0.20
Hist -0.02
ATR (14)
0.16
15.17% of price
Realised vol 30D
106.5%
Annualised
Bollinger upper
2.03
20, 2σ
Bollinger lower
0.91
20, 2σ
50 / 200 cross
Death
1.73 vs 3.05
Trend bias
Below 200
-64.57%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.47
Less volatile than market
Correlation to SPY
0.04
Largely independent
Realised vol 30D
106.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-97.5%
Peak to trough
Max drawdown 5Y
-99.8%
Peak to trough
ATR 14
0.16
15.17% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
255.53K
Prior 173.31K
Change vs prior
+47.4%
Shorts adding
% of float
1.92%
Normal
% of shares out
1.92%
Against total outstanding
Days to cover
2.0
Liquid
Float
9.63M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 30, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jul 8, 26 | Raymond James | UPGRADE | Market Perform | Outperform |
| Jul 7, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 8, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
| Apr 20, 26 | Barclays | DOWNGRADE | Equal-Weight | Underweight |
| Apr 1, 26 | Barclays | MAINTAINED | Equal-Weight | Equal-Weight |
| Apr 1, 26 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Apr 1, 26 | BTIG | MAINTAINED | Buy | Buy |
| Oct 14, 25 | Raymond James | DOWNGRADE | Outperform | Market Perform |
| Oct 13, 25 | BTIG | MAINTAINED | Buy | Buy |
| Oct 13, 25 | Barclays | INITIATED | — | Overweight |
| Jul 14, 25 | Raymond James | INITIATED | — | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:3
Split dateApr 16, 2025
SEC filings
Periodic Financial Reports
10-Q · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-07-30
Corporate Changes & Voting Matters
8-K · 2026-07-07
Corporate Changes & Voting Matters
8-K · 2026-06-11
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-05-08
Offering Registrations
S-3 · 2026-05-01
Proxy Statements
DEFA14A · 2026-04-23
Offering Registrations
S-8 · 2026-04-01
Headlines
New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
GlobeNewswire · 13d ago
Tvardi Therapeutics to Participate in Upcoming Investor Events
GlobeNewswire · 42d ago
Tvardi: Q2 Earnings Snapshot
Associated Press · 54d ago
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
GlobeNewswire · 54d ago
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
GlobeNewswire · 56d ago
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
GlobeNewswire · 69d ago
Piper Sandler Upgrades Tvardi Therapeutics to Overweight From Neutral, Adjusts Price Target to $13 From $3
MT Newswires · 90d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.